Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement

Angela Dispenzieri, S Vincent Rajkumar, Morie Gertz, Rafael Fonseca, Martha Lacy, Peter Leif Bergsagel, Robert A. Kyle, Philip R. Greipp, Thomas Elmer Witzig, Craig B. Reeder, John A. Lust, Stephen J Russell, Suzanne R. Hayman, Vivek Roy, Shaji K Kumar, Steven R. Zeldenrust, Robert J. Dalton, Alexander Keith Stewart

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, β2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.

Original languageEnglish (US)
Pages (from-to)323-341
Number of pages19
JournalMayo Clinic Proceedings
Volume82
Issue number3
DOIs
StatePublished - 2007

Fingerprint

Multiple Myeloma
Consensus
Paraproteinemias
Tumor Burden
Serum Albumin
Decision Making
Therapeutics
Quality of Life
Kidney
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{99caaffc6da6495d8f1ab58c413f3fa6,
title = "Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement",
abstract = "Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, β2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.",
author = "Angela Dispenzieri and Rajkumar, {S Vincent} and Morie Gertz and Rafael Fonseca and Martha Lacy and Bergsagel, {Peter Leif} and Kyle, {Robert A.} and Greipp, {Philip R.} and Witzig, {Thomas Elmer} and Reeder, {Craig B.} and Lust, {John A.} and Russell, {Stephen J} and Hayman, {Suzanne R.} and Vivek Roy and Kumar, {Shaji K} and Zeldenrust, {Steven R.} and Dalton, {Robert J.} and Stewart, {Alexander Keith}",
year = "2007",
doi = "10.4065/82.3.323",
language = "English (US)",
volume = "82",
pages = "323--341",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART)

T2 - Consensus statement

AU - Dispenzieri, Angela

AU - Rajkumar, S Vincent

AU - Gertz, Morie

AU - Fonseca, Rafael

AU - Lacy, Martha

AU - Bergsagel, Peter Leif

AU - Kyle, Robert A.

AU - Greipp, Philip R.

AU - Witzig, Thomas Elmer

AU - Reeder, Craig B.

AU - Lust, John A.

AU - Russell, Stephen J

AU - Hayman, Suzanne R.

AU - Roy, Vivek

AU - Kumar, Shaji K

AU - Zeldenrust, Steven R.

AU - Dalton, Robert J.

AU - Stewart, Alexander Keith

PY - 2007

Y1 - 2007

N2 - Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, β2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.

AB - Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, β2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.

UR - http://www.scopus.com/inward/record.url?scp=33847369790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847369790&partnerID=8YFLogxK

U2 - 10.4065/82.3.323

DO - 10.4065/82.3.323

M3 - Article

C2 - 17352369

AN - SCOPUS:33847369790

VL - 82

SP - 323

EP - 341

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -